HARROW INC (HROW) Stock News

USA - NASDAQ:HROW - US4158581094 - Common Stock

42.13 USD

+2.12 (+5.3%)

Last: 10/20/2025, 8:00:01 PM

41.22 USD

-0.91 (-2.16%)

Pre-Market: 10/21/2025, 8:49:19 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

HROW Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: Harrow, Inc.

ImprimisRx Announces Leadership Changes

25 days ago - By: Benzinga

Could Harrow's New Sedation Pill Change Millions Of Medical Procedures Forever?

25 days ago - By: Stocktwits - Mentions: VTWG IWV

News Image

Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside

25 days ago - By: Harrow, Inc.

Harrow to Acquire Melt Pharmaceuticals

26 days ago - By: Harrow, Inc.

Harrow Launches Harrow Access for All (HAFA)

a month ago - By: Benzinga

Demystifying Harrow: Insights From 5 Analyst Reviews

2 months ago - By: Zacks Investment Research - Mentions: NVT ECG

Best Momentum Stock to Buy for August 15th

a month ago - By: Harrow, Inc.

Harrow Announces Agenda and Speakers for Investor & Analyst Day

a month ago - By: Harrow, Inc.

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

a month ago - By: Harrow, Inc.

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

2 months ago - By: Zacks Investment Research

Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock

2 months ago - By: Zacks Investment Research

Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

2 months ago - By: Harrow, Inc.

Harrow Announces Second-Quarter 2025 Financial Results

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

3 months ago - By: Harrow, Inc.

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

3 months ago - By: Zacks Investment Research - Mentions: ACRS

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW

3 months ago - By: Harrow, Inc.

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW